Poly Group, LLC was formed in 2010 and, soon after, secured the exclusive worldwide rights to HBP technology from the Purdue Research Foundation. Proof of concept continued and by the end of 2011, the company was raising capital. A research laboratory was set up headed by Craig Kalmer and Thomas Hopkins, Ph.D. Both had extensive experience in pharmaceutical research and production and both were former executives in other companies.
A patent for the technology, now branded as Nouvex™, was secured in late 2012 and the company signed its first joint development agreement. In 2013, the Company moved to the Purdue Research Center of Southeast Indiana in New Albany, Indiana. A detailed testing strategy for obtaining the proper approvals from the US Environmental Protection Agency (EPA) was established in preparation for taking Nouvex to market.
As progress allowed, the company continued to methodically raise capital to finance the proper EPA-mandated efficacy and toxicology testing. The testing continued with outstanding results and by the summer of 2014, all research required to file the proper EPA applications had been successfully completed. After completing and assembling the required documentation, the EPA application was submitted in early 2015 and, after a two-year process, Nouvex received a registration from the U.S. Environmental Protection Agency (EPA), Office of Pesticide Programs, Antimicrobial Division as a material preservative; EPA Reg. No. 91413-2. Labeling and notice identifications were approved soon thereafter.
Testing continues and additional patent applications have been filed and work continues to expand and add to our EPA registration.
Poly Group, LLC has opportunities for joint development with companies who are interested in improving current antimicrobial products or developing new applications with antimicrobial properties. Exclusive marketing options are also available. Such arrangements will include a variety of non-disclosure documentation, option fees, and research requirements.